Trials / Completed
CompletedNCT00618618
Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat
Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Given by Three Dosing Paradigms for the Reduction of Localized Subcutaneous Fat in the Submental Area
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- Kythera Biopharmaceuticals · Industry
- Sex
- All
- Age
- 25 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Phase 2 trial to evaluate the safety and potential efficacy of one concentration of deoxycholic acid injection, given in three dosing paradigms, compared to placebo for the reduction of submental fat (fat beneath the chin).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deoxycholic Acid Injection | Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL. |
| DRUG | Placebo |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2008-02-20
- Last updated
- 2015-07-14
- Results posted
- 2015-06-15
Locations
7 sites across 3 countries: Australia, Canada, United Kingdom
Source: ClinicalTrials.gov record NCT00618618. Inclusion in this directory is not an endorsement.